Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9250)	5/18/2002 2:31:43 PM
From: ewolf	Respond to of 9719

On melacine--Not exactly. They negotiated the design for a second phase 3 with the fda. It remains unclear when that trial can be completed(years?) before they can gain approval. The company has a lot going on but most of it feels like sand passing through the hourglass. I don't have a clue what chance they have for survival without bexxar. Came into this through Coulter. They should write a book about Bexxar in the fda maelstrom some day as a primer on why seemingly good drugs can fail. Thanks, eaw